Arca Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ABIO 1.17 +0.02 (2.17%)
price chart
ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference
WESTMINSTER, Colo., Sept. 21, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today ...
BRIEF-Arca Biopharma Inc says it entered into amendment no. 1 to its capital ...
BRIEF-Arca Biopharma Inc says it entered into amendment no. 1 to its capital on demand sales agreement. Reuters Staff. 1 Min Read.
Will You Be Burnt By ARCA biopharma Inc's (ABIO) Cash Burn?
ARCA biopharma Inc (NASDAQ:ABIO) announced a loss of -$18.76M in its most recent earnings update. Although some investors expected this, their belief in the path to profitability for ABIO may be wavering.
ARCA Biopharma: Low Valuation On Past Failures, High Upside And Limited Risk ...
ARCA Biopharma (NASDAQ: ABIO) is a development stage biotech company that has been beaten down over several decades. Their flagship therapeutic candidate, Gencaro� is a beta-blocker that has seen multiple efficacy issues in outcomes measures.
ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides ...
WESTMINSTER, Colo., Aug. 03, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today ...
Why Arca Biopharma Is A Buy
Arca Biopharma (NASDAQ:ABIO) is a pre-revenue company that has patents through 2029 covering the drug Gencaro (generic: bucindolol).
Who Really Owns ARCA biopharma Inc (ABIO)?
In this article, I'm going to take a look at ARCA biopharma Inc's (NASDAQ:ABIO) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.
Pre-Bell Stock Alert on ARCA biopharma, Inc. (NASDAQ:ABIO) and Opiant ...
Opiant Pharmaceuticals, Inc. (OTCMKTS:OPNT) shares are gapping higher 2.11% pre-market with a price of $37.75 on the stock.
Anders Hove, MD Joins ARCA biopharma Board of Directors
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that ...
Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial
WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the ...